Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Conditions:   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   CD22 Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia Interventions:   Biological: Blinatumomab;   Biological: Inotuzumab Ozogamicin Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials